By continuing to browse this site you agree to us using cookies as described in About Cookies
Notice: Wiley Online Library will be unavailable on Saturday 7th Oct from 03.00 EDT / 08:00 BST / 12:30 IST / 15.00 SGT to 08.00 EDT / 13.00 BST / 17:30 IST / 20.00 SGT and Sunday 8th Oct from 03.00 EDT / 08:00 BST / 12:30 IST / 15.00 SGT to 06.00 EDT / 11.00 BST / 15:30 IST / 18.00 SGT for essential maintenance. Apologies for the inconvenience.
The clinical presentation of primary biliary cirrhosis (PBC) has changed significantly in recent decades, and now most patients are asymptomatic middle-aged women with (1) abnormal liver chemistries, particularly mild elevations of alkaline phosphatase (AP), gamma-glutamyltransferase (GGT), and aminotransferases, and (2) early histological stages of the disease.[1, 2] These changes are associated with long-term survival; consequently, the main goal of therapy is to improve cholestasis and thus prevent the progression of liver damage that eventually results in liver cirrhosis and reduced survival free of transplantation. Additionally, the slow progression of the disease limits the hard endpoints of death or liver transplantation for treatment efficacy; therefore, response to treatment is defined as improvement or lack of progression in biochemical markers, liver histology, or the consequences of portal hypertension.
Because of the presumed immunologic pathogenesis of the disease, a number of randomized and observational and pilot studies were performed in the 1980s assessing the effect of several agents, including azathioprine, chlorambucil, methotrexate, mycophenolate mofetil, prednisone, and cyclosporine. Other agents have been evaluated as well, including penicillamine, colchicine, malotilate, thalidomide, silymarin, and atorvastatin. No clear or even deleterious consequences were derived from these studies.[1, 2]
Ursodeoxycholic Acid and Biochemical Criteria for Optimal Response
Over the past two decades, increasing evidence has indicated that ursodeoxycholic acid (UDCA) at 13-15 mg/kg/day is the treatment of choice for patients with PBC based on placebo-controlled trials and more recent long-term case-control studies. UDCA markedly decreases serum bilirubin, AP, GGT, cholesterol and immunoglobulin M (IgM) levels, and ameliorates histological features in patients with PBC. Moreover, long-term treatment with UDCA delays the histological progression of the disease (Fig. 1), mainly in patients with early histological stage.[1, 2] Despite these favorable effects, the use of UDCA in patients with PBC has been questioned, because no clear benefit in survival or time to liver transplantation have been demonstrated in different meta-analyses and in the Cochrane Database of Systematic Reviews. However, it should be noted that in some trials, most patients were asymptomatic and at the initial stages of the disease. Therefore, UDCA should be given for much longer periods to confirm apparent changes on survival free of liver transplantation. More recently, a number of studies have shown that biochemical response to UDCA, as indicated by improvement of one or more biochemical tests, assessed at 1 year and 6 months clearly predict the long-term outcome, since in UDCA responders the survival is similar to that estimated for the matched control population (Fig. 2). Several definitions of optimal biochemical response to UDCA have been proposed (Table 1),[5-11] and ∼40% of patients fulfill at least one condition of incomplete biochemical response. These patients have an increased risk of progression events, and decreased survival free of transplantation. Therefore, the patients with suboptimal biochemical response to UDCA outline the group of patients in whom further single or combined treatments with UDCA are needed. Accordingly, data on the effect of fibrates alone or in combination with UDCA and budesonide in combination with UDCA have been reported. The effect of new agents have been reported, including obeticholic acid; however, this particular agent is not commercially available. Apart from these agents, antiretroviral treatments have been proposed, but the results are meager and the rationale based on the hypothesis of a possible retroviral etiology of PBC has not been validated.[1, 2] Molecular therapies with antibodies against B cells and interleukins are currently being investigated.
Early studies from Japan described an improvement of biochemical cholestasis and liver histology when giving fibrates (bezafibrate or fenofibrate) in patients with PBC. More recently, treatment with fibrates in PBC has been evaluated in Western countries with similar results regarding to the improvement of cholestasis and cytolysis[12-15] (Table 2). Adding fenofibrate (160 mg/day) for 1 year in 20 patients without biochemical optimal response to UDCA, as defined by the Barcelona criteria, resulted in a significant decrease in cholestasis and cytolysis and other markers of inflammation, such as interleukin-1 and interleukin-6.13 These data are consistent with the study performed in our center, which has evaluated 30 patients with PBC without biochemical response to UDCA or with AP levels 1.5 times the upper limit of normal. The addition of bezafibrate (400 mg/day) to UDCA has favorable effects; this combined treatment results in normalization or a dramatic decrease of markers of cholestasis (Fig. 3) and cytolysis after 1 year, as well as a noticeable decrease of itching. Discontinuation of bezafibrate for 3 months was associated with a significant elevation of biochemical markers and development of itching. These favorable consequences were more relevant in patients with lower severity and early disease as measured by transient elastography. No severe adverse effects resulting from combined treatment with fibrates have been described, but some patients have experienced heartburn or nausea, resulting in treatment discontinuation. The anticholestatic mechanisms of fibrates are not completely elucidated, but the main action may result from being perixosome proliferator-activated receptor agonists with multiple targets regulating bile-transporter expression and inflammation. Moreover, fibrates up regulate the expression of multiple drug resistance gene-3.
Table 1. Biochemical Criteria of Optimal Response to UCDA in PBC
In summary, data from all of the aforementioned studies suggest that combined treatment with fibrates in patients without optimal biochemical response to UDCA could be useful, because it would improve the degree of cholestasis and may minimize the long-term management of these patients; however, more studies are already needed. A phase 3 trial is ongoing in Europe to assess bezafibrate as an assisting therapy to UDCA (ClinicalTrials.gov identifier: NCT01654731).
Budesonide is a nonhalogenated glucocorticoid absorbed in the small intestine with 90% first-pass hepatic metabolism in healthy individuals and with glucocorticoid receptor-binding activity higher than prednisolone. Two randomized trials showed that the combination of budesonide (6-9 mg/day) with UDCA is more effective for improving liver biochemistries and histology than UDCA alone in patients with PBC who do not have cirrhosis.[16, 17] In a recent 3-year prospective, randomized study of 77 patients, serum liver enzymes decreased significantly in both treatment arms, but histological stage and fibrosis improved in the combined treatment group and deteriorated in the UDCA group. The same positive effect of combination therapy on liver histology (stage, fibrosis, and inflammation) and laboratory values was observed by Leuschner et al., but with a higher dose of budesonide (9 mg/day) during 2 years of therapy. Angulo et al. reported minimal further benefits to UDCA after adding budesonide (9 mg/day) for 1 year in a pilot study of 22 PBC patients who had shown an incomplete response to UDCA. Mild glucocorticoid-related side effects were associated with budesonide treatment.
Although these results are remarkable, the effect of combined treatment with budesonide should be established in a large randomized trial that is currently being evaluated in Europe (EudraCT Number: 2007-004040-70). Meanwhile, this treatment can be assayed in patients without optimal UDCA biochemical response, and probably in patients with higher indices of inflammation.
Obeticholic acid (6-alpha-ethyl-chenodeoxycholic acid) is an innovative synthetic derivative of chenodeoxycholic acid, being 100 times more potent as a farnesoid X receptor (FXR) agonist. The FXR is expressed in the liver, intestine, adrenal glands, and kidneys and plays an important role in the enterohepatic circulation of bile acids. Among other functions, including the regulation of key aspects of carbohydrate and lipid metabolism, FXR reduces bile acid synthesis acting on the enzyme cholesterol 7α hydroxylase and also by down-regulating the expression of the sodium/taurocholate cotransporting peptide, a bile acid uptake protein. In addition, FXR activation increases expression of the bilirubin and phospholipid (multiple drug resistance gene-3) export pumps and FXR also stimulate intestinal factors such as fibroblast growth factor 19, which provide a negative feedback loop from the intestine to hepatocytes, contributing to repression of bile acid synthesis. In a phase 2 efficacy and safety assessment in PBC patients, addition of obeticholic acid in patients with stable UDCA dosage and with increased AP levels resulted in an ∼25% reduction of AP compared with placebo, with a parallel decrease of aminotransferase, GGT, and IgM levels, as well as one surrogate marker of bile acid synthesis. These effects were associated with a high incidence of pruritus with a dose-response relationship, leading to drug discontinuation in some patients. A long-term phase 3 trial of obeticholic acid in UDCA-treated patients based on an up-titration assessment of this new agent is currently ongoing (ClinicalTrials.gov identifier: NCT01473524).
Obeticholic acid alone in patients with PBC resulted in a favorable biochemical effect in another trial with 50% reduction in AP levels. Again, aminotransferase, GGT, and IgM levels decreased significantly with obeticholic acid, although pruritus probably resulted from the high dosage of this agent. A 12-month extension trial showed a sustained biochemical response (EudraCT Number: 2011-004728-36).
Approximately 40% of PBC patients receiving standard doses of UDCA (13-15 mg/kg/day) had a suboptimal response, defined by different plain biochemical tests. These criteria characterize the group of patients requiring further treatments. The information available has been insufficient thus far, but the favorable effects of adding fibrates and budesonide to UDCA are encouraging and represent something to offer patients who do not have an optimal response. A new agent, obeticholic acid, is under evaluation with clear favorable biochemical effects on cholestasis and inflammatory response; in addition, molecular therapies with antibodies against B cells and interleukins are currently being investigated. At present, a practical recommendation in patients with suboptimal response to UDCA will be adding fibrates or budesonide according to the stage of the disease and the indices of inflammation. Addition of obeticholic acid will depend on the results of the ongoing trial, and it is important to note that the long-term beneficial effects of adding these agents are linked to the results of appropriate placebo-controlled trials.